Milrinone
Executive Summary
On Oct. 24, the Cardio-Renal Advisory Committee also will look at results of the 21-month Prospective Randomized Milrinone (BRACKET)Sterling's Primacor(BRACKET) Survival Evaluation (PROMISE). Interim results of the trial, which was completed in September 1990, caused Sterling to discontinue development of its phosphodiesterase III inhibitor. On Oct. 25, the committee will discuss antihypertensive drug development. The meeting is scheduled for Jack Masur Auditorium on the NIH campus from 9 a.m.- 5 p.m. each day. . . .